Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

January
05
2022

Sensus Healthcare Expects Record 4Q 2021 Sales and Continued Growth in 1Q 2022; Profiles New Product at the 2022 Winter Clinical Dermatology Conference

Expects profitability for the 2021 fourth quarter and full year Physician KOL presentation at the Winter Clinical to highlight the TransDermal Infusion System™ BOCA RATON, Fla., Jan. 05, 2022 — Sensus Healthcare, Inc. (Nasdaq: SRTS),…

December
17
2021

The Alternative Skin Cancer Treatment

If you’ve been diagnosed with skin cancer, you might be wondering what your options are when it comes to your treatment. For nearly 90 years, Mohs surgery has been the procedure of choice to treat…

December
13
2021

The Dermatology Digest – Superficial Radio Therapy Clinical Benefits and Studies

Not all treatment modalities for non-melanoma skin cancer are the same. In Part 2 of this video series, Dr. Mark Nestor discusses studies that demonstrate the clinical benefits of SRT, including cure rate, cosmesis, and…

December
01
2021

Sensus Healthcare Signs Exclusive U.S. Distribution Agreement with Mattioli Eng. Italia for its TransDermal Infusion System

Sensus to Bring FDA-cleared Non-invasive Drug-delivery System and Treatment Alternative to Needles to Dermatologists Beginning [Immediately/Date] BOCA RATON, Fla, Dec. 01, 2021 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy